Skip to search formSkip to main contentSkip to account menu

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack

Results from the study of the 3 NOACs versus warfarin in nonvalvular atrial fibrillation patients with a previous history of stroke/ transient ischemic attack are relatively consistent with their respective phase III trials and previous stroke/transient isChemic attack subgroup analyses.
Wolters Kluwer (opens in a new tab)

Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin

In patients with PE, rivaroxaban was associated with reduced LOS and costs, without increased risk of readmission versus parenterally bridged warfarin, and similar results were observed in low-risk PE patients.
Springer (opens in a new tab)

Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke.

PubMed (opens in a new tab)

Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis

The pooled rates of major bleeding with rivaroxaban were generally low and consistent with those reported in its pivotal randomized controlled trial.
Taylor & Francis (opens in a new tab)

Validation of the multivariable In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) prediction rule within an all-payer inpatient administrative claims database

The IMPACT rule appeared valid when used in this all payer, inpatient only administrative claims database, and its high sensitivity and NPV suggest the probability of in-hospital death in those classified as low risk by IMPACT was minimal.
BMJ Publishing Group (opens in a new tab)

Abstract 13112: Benefit of Early Discharge Among Patients With Low-risk Pulmonary Embolism: Focus on Net Clinical Impact

LRPE patients with short LOS had better net clinical outcomes at lower costs than those with long LOS, and providers should deploy risk stratification strategies and consider early discharge for LRPE patients.
Publisher (opens in a new tab)

Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice.

PubMed (opens in a new tab)

The value of sPESI for risk stratification in patients with pulmonary embolism

Using the simplified Pulmonary Embolism Severity Index (sPESI) as a risk-stratification method to understand the Veterans Health Administration PE population identifies a PE cohort with a lower clinical and economic burden.
Springer (opens in a new tab)

Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?

Rivaroxaban significantly reduced hospital LOS and costs compared to parenterally bridged warfarin, without increasing the risk of readmission.
SAGE (opens in a new tab)

External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans

IMPACT appears useful for identifying PE patients at low risk for early mortality or readmission in claims-based studies, and similar trends were observed for VTE or major bleeding readmissions.
Springer (opens in a new tab)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)
  NODES
admin 3
Association 1
INTERN 3
Note 1